Drugs / KH607
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07634874 | Jun → Jul 2026 overdue | — | Chengdu Kanghong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06393803 | Oct 2023 → Oct 2024 | — | Chengdu Kanghong Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07101120 | Aug → Dec 2025 overdue | major depressive disorder | Chengdu Kanghong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07096791 | Jul 2025 → Jan 2027 expected | postpartum depression | Chengdu Kanghong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KH607 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07634874 ↗ |
| Route | Oral | “Subject receive KH607 tablets or placebo orally single dose.” NCT06393803 ↗ |